Clinical trial
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
NCT00272311 · Florida Atlantic University, Other · Completed
Key facts
| NCT number | NCT00272311 |
|---|---|
| Title | Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome |
| Official title | A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome) |
| Acronym | PAD |
| Lead sponsor | Florida Atlantic University, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis |
| Intervention type | Drug |
| Interventions | Aspirin |
| Enrollment | 70 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jan 5, 2006 |
| Last update posted | Feb 27, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: